Monographie - Spironolactone - Stabilis 4.0

Utolsó frissítés :
08/05/2024

Vizelethajtó

Spironolactone

Belsőleges oldat

Stabilitása gyógyszerészeti készítmények

A keverékek stabilitása

Stabilitást befolyásoló tényezők

Kompatibilitás

Irodalom

Pdf

Kémiai szerkezet

Belsőleges oldat

Irodalom

Belsőleges oldat

Irodalom : Spironolactone

	Type	Publikáció
2435	Napló	Allen LV, Jr, Erickson MA, Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
2441	Napló	Allen LV, Jr, Erickson MA, Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2073-2078.
2489	Napló	Mathur LK, Wickman A Stability of extemporaneously compounded spironolactone suspensions Am J Hosp Pharm 1989 ; 46: 2040-2042.
2534	Napló	Nahata MC, Morosco RS, Hipple TF. Stability of spironolactone in an extemporaneously prepared suspension at two temperatures Ann Pharmacotherapy 1993 ;27:1198-1199.
2556	Napló	Peterson GM, Meaney MF, Reid CA. Stability of extemporaneously prepared mixtures of metoprolol and spironolactone. Aust J Hosp Pharm 1989 ; 19,: 344-346.
2559	Napló	Mc Knight DL. The formulation of spironolactone solution for paediatric use. Aust J Hosp Pharm 1993 ; 23: 83.
2854	Napló	Alexander KS, Sundar S, White DB, Dollimore D. The Formulation Development and Stability of Spironolactone Suspension Int J Pharm Compound 1997 ; 1, 3: 195-199.
2928	Napló	Salgado AC, Rosa ML, Duarte MA et al. Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations. EJHP Science 2005 ; 11: 68-73.
3810	Napló	Geiger C M, Sorenson B, Whaley P. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. Int J Pharm Compound 2015 ; 19, 5 : 420-427.
4000	Napló	Graves R, Phan K.V,Bostanian L.A,Mandal T.K, Pramar Y.V. Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt. Int J Pharm Compound 2017 ; 21:4 :334-338
4177	Napló	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4198	Napló	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201
4256	Napló	Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A. Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. Pharmaceutics 2019 ;11,190:

Mentions Légales